Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...

BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment ...

Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...

Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI ® ” (brand name in China: “??? ® ”, ...

Trackonomy reports that global supply chains face increasing challenges from climate disruptions and cyberattacks, making ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth ...

A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the ...

Japan’s tooth-regrowth breakthrough changes everything Losing teeth has meant artificial replacements for centuries. Japanese ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Biogen BIIB will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter ...

Hospitalized children should receive isotonic fluids such as 0.9% normal saline rather than hypotonic solutions for routine maintenance: This standard practice significantly reduces the risk of ...